

# Alessandro Vitale

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4573279/alessandro-vitale-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

173 papers	4,282 citations	35 h-index	59 g-index
229 ext. papers	5,128 ext. citations	3.7 avg, IF	5.04 L-index

#	Paper	IF	Citations
173	Prospective validation of the Barcelona Clinic Liver Cancer staging system. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 723-31	13.4	323
172	Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. <i>Annals of Surgery</i> , <b>2004</b> , 239, 150-9	7.8	247
171	The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?. <i>Journal of Hepatology</i> , <b>2004</b> , 40, 124-31	13.4	138
170	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 617-24	13.4	129
169	Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. <i>Lancet Oncology</i> , <b>2011</b> , 12, 654-62	21.7	114
168	Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 552-559	13.4	110
167	Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. <i>American Journal of Transplantation</i> , <b>2007</b> , 7, 972-81	8.7	100
166	Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?. <i>Cancer</i> , <b>2015</b> , 121, 3998-4006	6.4	91
165	Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. <i>Liver Transplantation</i> , <b>2009</b> , 15, 1278-87	4.5	90
164	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. <i>PLoS Medicine</i> , <b>2016</b> , 13, e1002006	11.6	81
163	Liver Transplantation during the COVID-19 pandemic: A quantitative model balancing individual patient benefit against population healthcare needs. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, S44	3.3	78
162	Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients. <i>American Journal of Transplantation</i> , <b>2011</b> , 11, 2724-36	8.7	77
161	Personalized treatment of patients with very early hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 412-423	13.4	75
160	Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. <i>Hepatology</i> , <b>2010</b> , 51, 165-73	11.2	75
159	A multicenter pilot prospective study comparing Celsior and University of Wisconsin preserving solutions for use in liver transplantation. <i>Liver Transplantation</i> , <b>2003</b> , 9, 814-21	4.5	75
158	A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 290-7	13.4	69
157	Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer. <i>Hepatology</i> , <b>2017</b> , 66, 1910-1919	11.2	65

156	Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma. <i>American Journal of Transplantation</i> , <b>2010</b> , 10, 619-27	8.7	64
155	Consensus conference on TIPS management: Techniques, indications, contraindications. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 121-137	3.3	60
154	Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 55-60	3.3	57
153	When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. <i>Hepatology</i> , <b>2015</b> , 61, 905-14	11.2	55
152	Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 2290-302	3.1	53
151	Circulating free DNA in the progression of liver damage to hepatocellular carcinoma. <i>Hepatology International</i> , <b>2013</b> , 7, 1050-7	8.8	52
150	Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. <i>Hepatology</i> , <b>2020</b> , 72, 2206-2218	11.2	49
149	Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. <i>Liver Transplantation</i> , <b>2011</b> , 17, 167-77	4.5	47
148	Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid?. <i>European Journal of Surgical Oncology</i> , <b>2008</b> , 34, 256-62	3.6	46
147	Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 440-445	3.3	45
146	SERPINB3 is associated with TGF- $\beta$ and cytoplasmic E-cadherin expression in hepatocellular carcinomas with poor prognosis. <i>British Journal of Cancer</i> , <b>2014</b> , 110, 2708-15	8.7	44
145	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 70-7	0.7	42
144	Use of N-acetylcysteine during liver procurement: a prospective randomized controlled study. <i>Liver Transplantation</i> , <b>2013</b> , 19, 135-44	4.5	42
143	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 455-467	3.3	41
142	De novo tumors are a major cause of late mortality after orthotopic liver transplantation. <i>Transplantation Proceedings</i> , <b>2009</b> , 41, 1303-5	1.1	41
141	Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on "number of patients needed to transplant" as measure of transplant benefit. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1165-71	13.4	38
140	Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. <i>Liver Transplantation</i> , <b>2017</b> , 23, 1103-1112	4.5	37
139	Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure?. <i>Transplantation</i> , <b>2010</b> , 89, 1425-9	1.8	36

138	Survival Benefit of Liver Transplantation Versus Resection for Hepatocellular Carcinoma: Impact of MELD Score. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 1901-7	3.1	35
137	Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. <i>Transplantation Proceedings</i> , <b>2009</b> , 41, 1260-3	1.1	35
136	Defining the possible therapeutic benefit of lymphadenectomy among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , <b>2016</b> , 113, 685-91	2.8	35
135	A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2019</b> , 31, 34-42	2.2	34
134	Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. <i>Cancer</i> , <b>2011</b> , 117, 125-33	6.4	34
133	The survival benefit of liver transplantation in hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 642-9	3.3	32
132	Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 232-52	5.6	31
131	Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center. <i>Journal of Vascular and Interventional Radiology</i> , <b>2017</b> , 28, 1495-1502	2.4	30
130	The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. <i>World Journal of Surgery</i> , <b>2015</b> , 39, 1474-84	3.3	30
129	BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. <i>Liver International</i> , <b>2015</b> , 35, 223-31	7.9	30
128	Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma. <i>Clinica Chimica Acta</i> , <b>2004</b> , 347, 129-38	6.2	29
127	A multi-institutional analysis of elderly patients undergoing a liver resection for intrahepatic cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , <b>2016</b> , 113, 420-6	2.8	29
126	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , <b>2019</b> , 39, 1478-1489	7.9	27
125	Development and Validation of a Comprehensive Model to Estimate Early Allograft Failure Among Patients Requiring Early Liver Re transplant. <i>JAMA Surgery</i> , <b>2020</b> , 155, e204095	5.4	27
124	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 1105-1114	3.3	26
123	Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis. <i>Annals of Surgery</i> , <b>2017</b> , 265, 792-799	7.8	25
122	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , <b>2019</b> , 11,	6.6	25
121	Risk factors in liver retransplantation: a single-center experience. <i>Transplantation Proceedings</i> , <b>2011</b> , 43, 1110-3	1.1	25

120	Skin cancer and other cutaneous disorders in liver transplant recipients. <i>Acta Dermato-Venereologica</i> , <b>2012</b> , 92, 411-5	2.2	25
119	Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?. <i>Transplantation Proceedings</i> , <b>2012</b> , 44, 1989-91	1.1	24
118	Liver transplantation using suboptimal grafts: impact of donor harvesting technique. <i>Liver Transplantation</i> , <b>2007</b> , 13, 1444-50	4.5	24
117	Liver transplantation for hepatocellular carcinoma through the lens of transplant benefit. <i>Hepatology</i> , <b>2017</b> , 65, 1741-1748	11.2	22
116	Laparoscopic microwave ablation in patients with hepatocellular carcinoma: a prospective cohort study. <i>Hpb</i> , <b>2014</b> , 16, 979-86	3.8	22
115	Microwave thermal ablation for hepatocarcinoma: six liver transplantation cases. <i>Transplantation Proceedings</i> , <b>2011</b> , 43, 1091-4	1.1	22
114	Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , <b>2007</b> , 95, 213-20	2.8	22
113	Age and equity in liver transplantation: An organ allocation model. <i>Liver Transplantation</i> , <b>2015</b> , 21, 1241-45	4.5	21
112	Liver autotransplantation for the treatment of unresectable hepatic metastasis: an uncommon indication-a case report. <i>Transplantation Proceedings</i> , <b>2012</b> , 44, 1930-3	1.1	21
111	Laparoscopic ablation of hepatocellular carcinoma in cirrhotic patients unsuitable for liver resection or percutaneous treatment: a cohort study. <i>PLoS ONE</i> , <b>2013</b> , 8, e57249	3.7	21
110	Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model. <i>Surgery</i> , <b>2015</b> , 158, 339-48	3.6	20
109	Liver transplantation for the management of hepatoblastoma. <i>Transplantation Proceedings</i> , <b>2003</b> , 35, 2983-5	1.1	20
108	Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC. <i>Cell Death and Disease</i> , <b>2019</b> , 10, 703	9.8	18
107	Progression of hepatocellular carcinoma before liver transplantation: dropout or liver transplantation?. <i>Transplantation Proceedings</i> , <b>2009</b> , 41, 1264-7	1.1	18
106	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , <b>2018</b> , 22, 859-871	3.3	17
105	Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 6920-5	5.6	17
104	Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. <i>Hepatology</i> , <b>2020</b> , 71, 569-582	11.2	17
103	Estimation of the harm to the waiting list as a crucial factor in the selection of patients with hepatocellular carcinoma for liver transplantation. <i>Transplantation Proceedings</i> , <b>2010</b> , 42, 1194-6	1.1	16

102	Adjuvant chemotherapy for transplanted hepatocellular carcinoma patients: impact on survival or HCV recurrence timing. <i>Transplantation Proceedings</i> , <b>2003</b> , 35, 2991-4	1.1	16
101	Transplant benefit for patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 9183-8	5.6	16
100	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , <b>2018</b> , 68, 1232-1244	11.2	15
99	Who fares worse after liver transplantation? Impact of donor and recipient variables on outcome: data from a prospective study. <i>Transplantation</i> , <b>2013</b> , 95, 1528-34	1.8	15
98	Liver Resection for Advanced Intrahepatic Cholangiocarcinoma: A Cost-Utility Analysis. <i>World Journal of Surgery</i> , <b>2015</b> , 39, 2500-9	3.3	14
97	Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. <i>Cancers</i> , <b>2019</b> , 11,	6.6	13
96	Donor-Model for End-Stage Liver Disease and donor-recipient matching in liver transplantation. <i>Transplantation Proceedings</i> , <b>2011</b> , 43, 974-6	1.1	13
95	Growth hormone/insulin-like growth factor 1 axis recovery after liver transplantation: a preliminary prospective study. <i>Liver Transplantation</i> , <b>2004</b> , 10, 692-8	4.5	13
94	Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial. <i>Liver Transplantation</i> , <b>2019</b> , 25, 242-251	4.5	13
93	Management and prognosis of hepatocellular carcinoma in the elderly: Results of an in-field multicenter cohort study. <i>Liver International</i> , <b>2017</b> , 37, 1184-1192	7.9	12
92	Management of hepatitis C infection before and after liver transplantation. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 4447-56	5.6	12
91	Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis. <i>Translational Research</i> , <b>2016</b> , 168, 122-133	11	12
90	A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the liver match study. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 340-7	3.3	12
89	Alcohol abuse and de novo tumors in liver transplantation. <i>Transplantation Proceedings</i> , <b>2009</b> , 41, 1310-2	1.1	12
88	Early surgery for the treatment of toxic megacolon. <i>Digestion</i> , <b>2005</b> , 72, 146-9	3.6	12
87	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. <i>Cancers</i> , <b>2021</b> , 13,	6.6	12
86	Readmission After Liver Resection for Intrahepatic Cholangiocarcinoma: a Multi-Institutional Analysis. <i>Journal of Gastrointestinal Surgery</i> , <b>2015</b> , 19, 1334-41	3.3	11
85	Prospective validation of a new priority allocation model for liver transplant candidates: an interim analysis. <i>Transplantation Proceedings</i> , <b>2009</b> , 41, 1092-5	1.1	11

84	Prognostic evaluation of the donor risk index among a prospective cohort of Italian patients undergoing liver transplantation. <i>Transplantation Proceedings</i> , <b>2009</b> , 41, 1096-8	1.1	11
83	Multimodal therapy before liver transplantation for hepatocellular carcinoma. <i>Hepatology Research</i> , <b>2005</b> , 31, 112-5	5.1	11
82	Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. <i>Expert Opinion on Drug Safety</i> , <b>2019</b> , 18, 603-610	4.1	10
81	The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation. <i>Liver Transplantation</i> , <b>2019</b> , 25, 1023-1033	4.5	10
80	Sorafenib use in the transplant setting. <i>Liver Transplantation</i> , <b>2014</b> , 20, 1021-8	4.5	10
79	Isoniazid-related fulminant hepatic failure in a child: assessment of the native liverWearly regeneration after auxiliary partial orthotopic liver transplantation. <i>Transplant International</i> , <b>2005</b> , 17, 713-6	3	10
78	Videolaparoscopic microwave ablation in patients with HCC at a European high-volume center: Results of 815 procedures. <i>Journal of Surgical Oncology</i> , <b>2019</b> , 120, 956-965	2.8	9
77	Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor. <i>Liver Transplantation</i> , <b>2015</b> , 21, 1250-8	4.5	9
76	Can liver transplantation provide the statistical cure?. <i>Liver Transplantation</i> , <b>2014</b> , 20, 210-7	4.5	9
75	Fibrosis progression and the pros and cons of antiviral therapy for hepatitis C virus recurrence after liver transplantation: a review. <i>Transplantation Proceedings</i> , <b>2010</b> , 42, 2223-5	1.1	9
74	Hepatitis C virus-related cirrhosis as a significant mortality factor in intention-to-treat analysis in liver transplantation. <i>Transplantation Proceedings</i> , <b>2007</b> , 39, 1901-3	1.1	9
73	Serum alkaline phosphatase, a risk factor for non-alcoholic fatty liver, but only for women in their 30s and 40s: evidence from a large cohort study. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2017</b> , 11, 269-276	4.2	8
72	Hepatic Resection for Disappearing Liver Metastasis: a Cost-Utility Analysis. <i>Journal of Gastrointestinal Surgery</i> , <b>2015</b> , 19, 1668-75	3.3	8
71	Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection. <i>Personalized Medicine</i> , <b>2020</b> , 17, 83-87	2.2	8
70	Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
69	Intensive care unit admission of decompensated cirrhotic patients: prognostic scoring systems. <i>Transplantation Proceedings</i> , <b>2011</b> , 43, 1079-84	1.1	8
68	Combined liver and kidney transplantation: analysis of Padova experience. <i>Transplantation Proceedings</i> , <b>2007</b> , 39, 1933-5	1.1	8
67	Global management of a common, underrated surgical task during the COVID-19 pandemic: Gallstone disease - An international survey. <i>Annals of Medicine and Surgery</i> , <b>2020</b> , 57, 95-102	2	8

66	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.. <i>Gut</i> , <b>2021</b> ,	19.2	8
65	Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation. <i>Transplant International</i> , <b>2015</b> , 28, 1055-65	3	7
64	Long-term results of liver transplantation for hepatocellular carcinoma: an update of the University of Padova experience. <i>Transplantation Proceedings</i> , <b>2007</b> , 39, 1892-4	1.1	7
63	Prognostic impact of model for end-stage liver disease score in patients undergoing liver transplantation with suboptimal livers. <i>Transplantation Proceedings</i> , <b>2007</b> , 39, 1907-9	1.1	7
62	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. <i>Cancers</i> , <b>2021</b> , 13,	6.6	7
61	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , <b>2021</b> , 41, 396-407	7.9	7
60	Selection of patients with hepatocellular cancer: a difficult balancing between equity, utility, and benefit. <i>Translational Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 75	5.2	6
59	Extreme marginal donor: severe hypothermia as a rare preservation condition for explantable organs--a case report. <i>Transplantation Proceedings</i> , <b>2003</b> , 35, 1282-4	1.1	6
58	Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
57	Risk Factors for Early Mortality in Liver Transplant Patients. <i>Transplantation Proceedings</i> , <b>2019</b> , 51, 179-183	1.1	5
56	Survival benefit of transplantation for recurrence of hepatocellular carcinoma after liver resection. <i>Transplantation Proceedings</i> , <b>2014</b> , 46, 2287-9	1.1	5
55	Model for end-stage liver disease-sodium and survival benefit in liver transplantation. <i>Transplant International</i> , <b>2013</b> , 26, 138-44	3	5
54	Urgency, utility, and time horizon of transplant benefit. <i>Liver Transplantation</i> , <b>2015</b> , 21, 565-6	4.5	5
53	Resection for hepatocellular cancer: overpassing old barriers. <i>Translational Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 64	5.2	5
52	Outcome of a First Episode of Bacterial Infection in Candidates for Liver Transplantation. <i>Liver Transplantation</i> , <b>2019</b> , 25, 1187-1197	4.5	4
51	Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 156-162	3.3	4
50	Liver radiofrequency ablation as emergency treatment for a ruptured hepatocellular carcinoma: a case report. <i>Journal of Medical Case Reports</i> , <b>2017</b> , 11, 54	1.2	4
49	A novel approach to severe acute pancreatitis in sequential liver-kidney transplantation: the first report on the application of VAC therapy. <i>Transplant International</i> , <b>2011</b> , 24, e23-7	3	4

48	Neoadjuvant therapy protocol and liver transplantation in combination with pancreatoduodenectomy for the treatment of hilar cholangiocarcinoma occurring in a case of primary sclerosing cholangitis: case report with a more than 8-year disease-free survival. <i>Transplantation Proceedings</i> , <b>2011</b> , 43, 1187-9	1.1	4
47	Pediatric liver transplantation: the University of Padua experience. <i>Transplantation Proceedings</i> , <b>2007</b> , 39, 1939-41	1.1	4
46	Syngeneic living-donor liver transplantation for hemangioendothelioma: a clinical model for studying liver regeneration. <i>American Journal of Transplantation</i> , <b>2005</b> , 5, 2309-14	8.7	4
45	Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies. <i>PLoS ONE</i> , <b>2011</b> , 6, e23093	3.7	4
44	A 2020 update on liver transplant for hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 885-900	4.2	4
43	International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. <i>JHEP Reports</i> , <b>2021</b> , 3, 100331	10.3	4
42	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
41	Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant. <i>JAMA Surgery</i> , <b>2021</b> , 156, e213112	5.4	4
40	Multimodal approach and its impact on survival for patients with hepatocellular carcinoma. <i>Anticancer Research</i> , <b>2003</b> , 23, 4047-53	2.3	4
39	Circulating MicroRNA-21 and MicroRNA-122 as Prognostic Biomarkers in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	3
38	Clinical results of active scanning proton therapy for primary liver tumors. <i>Tumori</i> , <b>2021</b> , 107, 71-79	1.7	3
37	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , <b>2021</b> , 10, 126-136	9.1	3
36	The NAFL Risk Score: A simple scoring model to predict 4-y risk for non-alcoholic fatty liver. <i>Clinica Chimica Acta</i> , <b>2017</b> , 468, 17-24	6.2	2
35	Estimation of Liver Transplant Related Survival Benefit: the Devil Is in The Details. <i>Gastroenterology</i> , <b>2016</b> , 150, 534-5	13.3	2
34	P915 PREDICTION OF RECURRENCE AFTER LIVER TRANSPLANTATION FOR HCC: VALIDATION OF THE AFP MODEL IN AN ITALIAN COHORT. <i>Journal of Hepatology</i> , <b>2014</b> , 60, S380	13.4	2
33	Liver transplantation in children with congenital cardiac defects: a case report and a short literature review. <i>Transplantation Proceedings</i> , <b>2013</b> , 45, 2769-73	1.1	2
32	108 A NOVEL MODEL OF PRIORITY ASSESSMENT FOR PATIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA ON A COMMON LIVER TRANSPLANT WAITING LIST: A MULTICENTRE, COHORT STUDY. <i>Journal of Hepatology</i> , <b>2013</b> , 58, S48	13.4	2
31	Prognostic prediction and identification of candidates for salvage liver transplantation among patients with early hepatocellular carcinoma. <i>Liver Transplantation</i> , <b>2014</b> , 20, 1150-1	4.5	2

30	Antiviral treatment for HCV recurrence after liver transplantation: when, how much and for how long?. <i>Future Virology</i> , <b>2011</b> , 6, 1179-1186	2.4	2
29	Liver resection associated with mini porto-caval shunt as salvage treatment in patients with progression of hepatocellular carcinoma before liver transplantation: a case report. <i>Transplantation Proceedings</i> , <b>2010</b> , 42, 1378-80	1.1	2
28	Alcohol- and substance-dependent subjects: the correlated factors in qualifying for liver transplantation. <i>Transplantation Proceedings</i> , <b>2007</b> , 39, 1861-3	1.1	2
27	Isoniazid-related fulminant hepatic failure in a child: assessment of the native liverWearly regeneration after auxiliary partial orthotopic liver transplantation. <i>Transplant International</i> , <b>2004</b> , 17, 713-716	3	2
26	SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences. <i>Biomarkers in Medicine</i> , <b>2020</b> , 14, 855-867	2.3	2
25	Analysis of clinical course of portal vein thrombosis in cirrhosis with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, S43	3.3	2
24	Transplantation for hepatocellular cancer: pushing to the limits?. <i>Translational Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 61	5.2	2
23	Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
22	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , <b>2021</b> ,	3.3	2
21	Which Is the True Role of Bridging Therapies for HCC Patients Waiting for Liver Transplantation?. <i>Annals of Surgery</i> , <b>2018</b> , 268, e56-e57	7.8	1
20	Circulating prostaglandin E: a novel potential prognostic biomarker in patients with hepatocellular carcinoma. <i>Clinical and Experimental Medicine</i> , <b>2021</b> , 21, 675-682	4.9	1
19	Liver Resection for Patients with Intermediate Stage Hepatocellular Carcinoma: Beyond Rigid Staging Systems Towards a More Personalized Therapeutic Approach. <i>Journal of Gastrointestinal Surgery</i> , <b>2021</b> , 25, 1078-1079	3.3	1
18	Thoracoscopic Ablation of Critically Located Liver Tumors: A Safety and Efficacy Cohort Study. <i>Frontiers in Surgery</i> , <b>2021</b> , 8, 626297	2.3	1
17	Liver transplantation for rare liver diseases and rare indications for liver transplant. <i>Translational Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 27	5.2	1
16	Colon Rectal Liver Metastases: The Role of the Liver Transplantation in the Era of the Transplant Oncology and Precision Medicine. <i>Frontiers in Surgery</i> , <b>2021</b> , 8, 693387	2.3	1
15	Changing indications for liver transplant: slow decline of hepatitis viruses in Italy. <i>Infectious Diseases</i> , <b>2020</b> , 52, 557-562	3.1	0
14	Reply: The easiest way to improve the outcome of suboptimal liver grafts. <i>Liver Transplantation</i> , <b>2008</b> , 14, 906-907	4.5	0
13	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 822507	5.3	0

12	R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.. <i>JHEP Reports</i> , <b>2022</b> , 4, 100445	10.3	0
11	NAFLD: a multi-faceted morbid spectrum with uncertain diagnosis and complicated management. <i>Minerva Surgery</i> , <b>2021</b> , 76, 450-466	0.1	0
10	Solid Organ Transplantation During COVID-19 Pandemic: An International Web-based Survey on Resource Allocation. <i>Transplantation Direct</i> , <b>2021</b> , 7, e669	2.3	0
9	Prognostic Factors for 10-Year Survival in Patients With Hepatocellular Cancer Receiving Liver Transplantation.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 877107	5.3	0
8	Liver Retransplantation for Hepatic Abscess Due to Hepatic Artery Thrombosis: A Case Report. <i>Transplantation Proceedings</i> , <b>2017</b> , 49, 736-739	1.1	
7	Reply. <i>Liver Transplantation</i> , <b>2017</b> , 23, 1630-1631	4.5	
6	Reply. <i>Hepatology</i> , <b>2018</b> , 67, 1639-1640	11.2	
5	Benefit and harm of deceased- or living-donor liver transplantation for hepatocellular carcinoma. <i>Digestive and Liver Disease Supplements</i> , <b>2009</b> , 3, 88-92		
4	New trends and perspectives in hepatobiliary surgery: preface. <i>Translational Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 99	5.2	
3	Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e14563-e14563	2.2	
2	A Novel Entity Among Vascular Liver Tumors: The First Reported Liver Transplantation. Is It Feasible?. <i>Transplantation Proceedings</i> , <b>2021</b> , 53, 1690-1693	1.1	
1	Reply. <i>Hepatology</i> , <b>2019</b> , 69, 465-466	11.2	